Haiyan Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haiyan Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Renfang Xu
Urology Department, Third Affiliated Hospital of Soochow University, Changzhou, China
2 shared publications- Abigail L. Sedlacek
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication Dong Xue
Urology Department, Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publicationHao Lu
Urology Department, Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publicationMelanie J. Scott
Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261
1 shared publicationQianfeng Zhuang
Urology Department, Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publication
Latest Publications
- Open Access
- 30 November 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 742, 151067
LXRα agonist differentially regulates BAFF expression and biological effects in RAW264.7 cells depending on growth status
- 30 November 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 742, 151067
Open AccessLXRα agonist differentially regulates BAFF expression and biological effects in RAW264.7 cells depending on growth status
- 15 October 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (8) , 2209-2214
Cutting Edge: The Heat Shock Protein gp96 Activates Inflammasome-Signaling Platforms in APCs
Several heat shock proteins (HSPs) prime immune responses, which are, in part, a result of activation of APCs. APCs respond to these immunogenic HSPs by upregulating costimulatory molecules and secreting cytokines, including IL-1β. These HSP-mediated responses are central mediators in pathological conditions ranging from cancer, sterile inflammation associated with trauma, and rheumatoid arthritis. We tested in this study the requirement of inflammasomes in the release of IL-1β by one immunogenic HSP, gp96. Our results show that murine APCs activate NLRP3 inflammasomes in response to gp96 by K+ efflux. This is shown to initiate inflammatory conditions in vivo in the absence of additional known inflammasome activators or infection. These results document a novel mechanism by which proteins of endogenous origin, the HSPs, can modulate an inflammatory response following their release from aberrant cells.
- 15 October 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (8) , 2209-2214
Cutting Edge: The Heat Shock Protein gp96 Activates Inflammasome-Signaling Platforms in APCs
Several heat shock proteins (HSPs) prime immune responses, which are, in part, a result of activation of APCs. APCs respond to these immunogenic HSPs by upregulating costimulatory molecules and secreting cytokines, including IL-1β. These HSP-mediated responses are central mediators in pathological conditions ranging from cancer, sterile inflammation associated with trauma, and rheumatoid arthritis. We tested in this study the requirement of inflammasomes in the release of IL-1β by one immunogenic HSP, gp96. Our results show that murine APCs activate NLRP3 inflammasomes in response to gp96 by K+ efflux. This is shown to initiate inflammatory conditions in vivo in the absence of additional known inflammasome activators or infection. These results document a novel mechanism by which proteins of endogenous origin, the HSPs, can modulate an inflammatory response following their release from aberrant cells.
- Open Access
- 6 June 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-5
B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome
Antibody-mediated rejection (ABMR) of renal allograft lacks typical phenotypes and clinical manifestations, always resulting in delayed diagnosis and treatment. It has been considered to be an elemental factor influencing the improvement of the long-term outcome of renal allograft. The B cell activating factor (BAFF) signal plays a fundamental function in the process of antibody-mediated immune response. Data from recipients and the nonhuman primate ABMR model suggest that the BAFF signal participates in the ABMR of renal allograft, while there are objections. The challenges in the diagnosis of ABMR, different study population, and details of research may explain the discrepancy. Large quantities of dynamic, credible data of BAFF ligands and their association with renal allograft pathological characteristics would constitute a direct proof of the role of BAFF in the progression of renal allograft ABMR.
- 6 June 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-5
Open AccessB Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome
Antibody-mediated rejection (ABMR) of renal allograft lacks typical phenotypes and clinical manifestations, always resulting in delayed diagnosis and treatment. It has been considered to be an elemental factor influencing the improvement of the long-term outcome of renal allograft. The B cell activating factor (BAFF) signal plays a fundamental function in the process of antibody-mediated immune response. Data from recipients and the nonhuman primate ABMR model suggest that the BAFF signal participates in the ABMR of renal allograft, while there are objections. The challenges in the diagnosis of ABMR, different study population, and details of research may explain the discrepancy. Large quantities of dynamic, credible data of BAFF ligands and their association with renal allograft pathological characteristics would constitute a direct proof of the role of BAFF in the progression of renal allograft ABMR.